MRK vs WFC: Which Is the Better Buy?
Side-by-side comparison of Merck & Co., Inc. and Wells Fargo & Company — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-05-20.
Merck & Co., Inc. · Healthcare
$114.27
+3.3% upside to fair value
Grade C
High Quality
VS
Wells Fargo & Company · Financial Services
$81.52
+30.6% upside to fair value
Grade B
QuantHub Verdict
WFC has more upside to fair value
(+30.6%).
WFC trades at a lower forward P/E
(11.9x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
MRK |
WFC |
| Current Price |
$114.27 |
$81.52 |
| Fair Value Estimate |
$118.00 |
$106.48 |
| Upside to Fair Value |
+3.3%
|
+30.6%
|
| Market Cap |
$282.2B |
$250.7B |
| Forward P/E |
22.4x
|
11.9x
|
| EV / EBITDA |
13.5x
|
16.7x
|
| Price / Sales |
4.3x
|
2.0x
|
| Price / FCF |
20.2x
|
-13.2x
|
| Revenue Growth YoY |
+5.0%
|
+7.3%
|
| Gross Margin |
81.9%
|
64.5%
|
| Operating Margin |
27.5%
|
20.5%
|
| Return on Equity |
5.6%
|
12.0%
|
| Dividend Yield |
2.91% |
0% |
| FCF Yield |
4.95%
|
—
|
| Analyst Consensus |
Overweight
|
Buy
|
Investment Thesis
Merck delivered a clean Q1 2026 operational beat on April 30, with revenue of 16.3 billion dollars growing 5 percent year over year and Keytruda sales rising 12 percent to 8.0 billion dollars. The reported loss of 1.28 dollars per share, though better than the negative 1.47 dollar consensus estimate, reflected a 3.62 dollar per share IPR and D charge tied to the Cidara Therapeutics acquisition an…
Wells Fargo & Company is a diversified financial services firm operating primarily in consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. The company benefits from a seasoned CEO with extensive industry experience and has made significant progress in regulatory compliance and operational efficiency, including lifting its asset cap in 2025.…
Accumulation Zones
| Metric |
MRK |
WFC |
| Zone Low |
$88.50 |
$79.86 |
| Zone High |
$100.30 |
$90.51 |
| In Buy Zone? |
No
|
Yes
|